Personalis, Inc. (PSNL)
| Previous close | 1.2500 |
| Open | 1.2604 |
| Bid | 1.2200 x 200 |
| Ask | 1.2800 x 200 |
| Day's range | 1.2500 - 1.2800 |
| 52-week range | 0.8910 - 2.6000 |
| Volume | |
| Avg. volume | 335,869 |
| Market cap | 65.036M |
| Beta (5Y monthly) | 1.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2500 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.75 |
Business WirePersonalis to Announce First Quarter 2024 Financial Results
FREMONT, Calif., April 24, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Business WirePersonalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
FREMONT, Calif., March 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.
Business WireData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
FREMONT, Calif., March 28, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.
